Tipifarnib Shows Responses in HRAS-Mutant Head and Neck Cancers

News
Article

A new inhibitor may help patients with a certain subset of head and neck squamous cell carcinoma.

A subset of metastatic head and neck squamous cell carcinoma (HNSCC) with mutations of the HRAS gene showed responses to the compound tipifarnib, an inhibitor of the enzyme farnesyltransferase, according to data presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics held in Boston from October 26, 2019 to October 30, 2019. The phase II results apply to roughly 5 to 8% of patients with advanced HNSCC who show the HRAS mutation. 

“Tipifarnib may represent a promising new therapy for HRAS-mutant HNSCC patients,” said Alan L. Ho, MD, PhD, a Memorial Sloan Kettering Cancer Center medical oncologist, and one of the lead investigators of the trial. “The success of the trial also speaks to the promise of utilizing genomic sequencing of disease to identify highly effective therapies that are personalized to the specific biology of each individual patient’s tumor.”

The latest look at the drug’s use in head and neck cancers was focused on 23 patients with HNSCC and 10 with other squamous cell carcinomas with HRAS mutations. All subjects had relapsed/refractory disease with a median of 2 prior treatments and had to have progressed on previous treatment (including platinum therapy, immunotherapy, or cetuximab). 

“The patients received a 600 mg dose of tipifarnib twice daily (1200 mg total) on days 1 through 7 and days 15 through 21 of the 28-day cycle, according to the data.”

Researchers said they met the durable response rate objective before the study was finished. The primary object was thus “amended to enrich for patients most likely to respond by recruiting only those patients with HNSCC tumors that had HRAS missense mutations at a high variant allele frequency (VAF; 35% or higher); those with a VAF of 20 % or higher were also enrolled if their baseline serum albumin was at least 3.5 g/dL.” The testing has prompted a start of first-line HRAS-mutation HNSCC tests, according to the abstract. 

“This is another example of how understanding the genomics and biology of a disease can be leveraged to develop new and effective cancer therapies,” concluded Ho. 

Tipifarnib has previously been tested in plexiform neurofibromas, as well as for AML, according to the literature available online. The latest study is sponsored by Kura Oncology.

References:

Ho A, Brana I, Haddad R, et al. Preliminary results from a phase 2 trial of tipifarnib in squamous cell carcinomas (SCCs) with HRAS mutations. Abstract presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Boston, October 26-30, 2019.


Kura Oncology. Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations.
Available from: https://clinicaltrials.gov/ct2/show/results/NCT02383927 .
ClinicalTrials.gov Identifier: NCT02383927. Accessed October 39, 2019.

Recent Videos
For example, you have a belt of certain diseases or genetic disorders that you come across, such as sickle cell disease or thalassemia, that are more prevalent in these areas.
Talent shortages in the manufacturing and administration of cellular therapies are problems that must be addressed at the level of each country.
Point-of-care manufacturing, scalable manufacturing, and bringing the cost down [can help].
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
A consolidated database may allow providers to access information on a patient’s prior treatments and genetic abnormalities all in 1 place.
A study presented at ASTRO 2025 evaluated the feasibility of using a unified cancer database to consolidate information gathered across 14 institutions.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ESMO Annual Congress, from hot topics and emerging trends to travel recommendations.
Physical therapists may play a key role in patient care before, during, and after treatment for cancer, according to Alison Ankiewicz, PT, DPT.
Related Content